Stuttgart
26.08.26 | 19:32
0,153 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,153 | 0,167 | 19:57 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:48 | Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer | 268 | Business Wire | Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients Original research conducted and funded by Korea's National Evidence-Based Healthcare... ► Artikel lesen | |
| 07.08. | Mauna Kea Technologies: Monthly information regarding the total number of voting rights and shares comprising the share capital | 503 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 28.07. | Mauna Kea Technologies Announces Two New Peer-Reviewed Clinical Studies Confirming the Clinical Value of Cellvizio and Its Combination with AI for the Diagnosis of Pancreatic Cysts | 459 | Business Wire | International interobserver study confirms increase of diagnostic accuracy to 96% for mucinous vs. non-mucinous, and higher physician agreement with Cellvizio AI Cellvizio increases accuracy... ► Artikel lesen | |
| 21.07. | Mauna Kea Technologies Reports Strong H1 2026 Core Sales Growth | 435 | Business Wire | H1 2026 sales reached €3,203K, up +44% at constant exchange rates (CER) and +39% as reported1 CellTolerance sales increased +145% to €0.9 million, driven by strong international expansion Strong... ► Artikel lesen | |
| 16.07. | Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity | 391 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces... ► Artikel lesen | |
| 16.07. | Mauna Kea Technologies Secures €4 Million Optional Shareholder Loan To Support Commercial Expansion | 2 | pulse2.com | ||
| 15.07. | Mauna Kea Technologies Secures €4.0M Shareholder Loan Agreement to Strengthen Liquidity and Fund Organic Growth | 677 | Business Wire | Shareholder loan agreement with long-term financial partner Vester Finance provides Mauna Kea with the contractual option to draw funds, with no obligation to do so, over the next 24 months Financing... ► Artikel lesen | |
| 06.07. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 303 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 04.06. | Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026 | 448 | Business Wire | All resolutions recommended by the Board of Directors were adopted, with the exception of the 15th
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio,... ► Artikel lesen | |
| 03.06. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 401 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.06. | Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying "Triple Healing", a Cellvizio- Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis | 334 | Business Wire | 100% of patients achieving Cellvizio-assessed triple healing remained relapse-free over 24 months (0 of 29), versus a ~33% relapse rate among those who did not A decade of converging, multi-center... ► Artikel lesen | |
| 20.05. | Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance Commercial Installation | 430 | Business Wire | IBS-related symptom prevalence in the region is among the highest in the world, reaching an average of 27% An ideal region uniquely positioned for CellTolerance's direct out-of-pocket commercial... ► Artikel lesen | |
| 18.05. | Mauna Kea Technologies Announces Nomination of 3 New Directors | 599 | Business Wire | Their recognized expertise will help accelerate the strategic transformation launched in 2025 Subject to approval at upcoming Annual General Meeting
Regulatory News:
Mauna Kea Technologies... ► Artikel lesen | |
| 04.05. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 359 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 30.04. | Mauna Kea Technologies: Publication of the 2025 Annual Financial Report | 826 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 28.04. | Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio To Be Presented at Digestive Disease Week 2026 | 763 | Business Wire | 10 Cellvizio-related abstracts, including landmark multicenter pancreatic cyst data, AI-driven IBD assessment, and new food intolerance applications, reinforce the breadth and depth of real-time... ► Artikel lesen | |
| 22.04. | Mauna Kea Technologies meldet starkes Wachstum im ersten Quartal 2026 | 1 | Investing.com Deutsch | ||
| 22.04. | Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025 | 857 | Business Wire | Fundamental balance sheet reset achieved through a 70% reduction in financial debt and €20M increase in equity Product sales momentum in 2025 driven by record U.S. sales performance (+38% CER)... ► Artikel lesen | |
| 15.04. | Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth | 458 | Business Wire | Q1 2026 sales reached €1,527K (excluding licensing), an increase of +68% at Constant Exchange Rate CER) and +57% as reported U.S. sales grew +34% CER (+21% reported) and +51% on an invoiced basis... ► Artikel lesen | |
| 08.04. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 373 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,065 | -6,07 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| FAMICORD | 2,810 | -1,75 % | FamiCord wechselt aus dem Prime Standard ins Scale-Segment | Die FamiCord AG wechselt mit Wirkung zum 19. August 2026 vom Prime Standard in das Scale-Segment der Frankfurter Wertpapierbörse. Die Deutsche Börse hat dem geplanten Schritt zugestimmt. Damit ist der... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,440 | -3,94 % | EQS-AFR: Geratherm Medical AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Geratherm Medical AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Geratherm Medical AG: Vorabbekanntmachung... ► Artikel lesen | |
| CERENOME | 2,540 | +0,40 % | Cerenome, Inc.: Cerenome Reports Second Quarter 2026 Financial Results and Business Update | HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics... ► Artikel lesen | |
| MEDICLIN | 5,450 | 0,00 % | Mediclin: Indirekter Profiteur | Sondersituationen wie Übernahmen, Turnarounds oder Abfindungsspekulationen sind gerade in der Spezialwerteszene eine beliebte Anlagestrategie. So rückte im Herbst 2025 etwa der auf den Reha-Bereich... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,300 | 0,00 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc. - 8-K, Current Report | ||
| VERU | 2,775 | +2,40 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| LIFEWARD | 7,380 | -0,14 % | H.C. Wainwright reiterates Lifeward stock rating on revenue growth | ||
| LIGHT AI | 0,135 | +6,32 % | Apple Launches Mac Studio Featuring New Chips Built for AI Workloads. Here's What Apple's Capital-Light AI Strategy Means for Investors. | ||
| IMUNON | 1,320 | +4,76 % | Imunon to host R&D day on Sept. 23 for ovarian cancer therapy | ||
| FRESENIUS | 46,345 | +1,09 % | Fresenius macht weitere 300 Millionen Euro bei FMC zu Geld | Fresenius trennt sich von weiteren 7,8 Millionen Aktien der Fresenius Medical Care (FMC) und erlöst damit rund 300 Millionen Euro. Das Paket entspricht etwa 2,9 Prozent des ausgegebenen FMC-Grundkapitals... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 39,260 | -1,11 % | Siemens-Healthineers-Chef: 'Mir gefällt dieses Rumgenörgel nicht' | BERLIN (dpa-AFX) - Der Vorstandvorsitzende des Dax -Konzerns Siemens Healthineers, Bernhard Montag, hat die Anspruchshaltung vieler Wirtschaftslenker in Deutschland gegenüber der Politik kritisiert.... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,360 | 0,00 % | Fresenius macht bei FMC Kasse - was jetzt zählt |
Das Unternehmen MAUNA KEA TECHNOLOGIES kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,153 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.